Our research division not only conducts various research studies to develop next generation biomedical diagnostics devices and software, but also participates in various national and international clinical trials of major pharmaceutical companies. Here are some of the clinical trials our company participates and provides support.
Xarelto + Acetylsalicylic Acid: Treatment patterns and outcomes in patients with Atherosclerosis. A non-interventional study. An Observational Study to observe the treatment patterns and outcomes in patients with Atherosclerosis. A non-Interventional study.
Blinded randomized trial of Anticoagulant to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation: is the blinded randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation.
Atrial fibrillation screening and make screening sustainable. Aware AF is the study to screen the Atrial fibrillation with the help of 7 days Holter (CardioSTAT devices).
Measurement of NT-proBNP for the diagnosis and assessment of congestive heart failure.
Patient registry assessing effectiveness and safety of Heart failure treatment with LCZ696 across Canada: (Sacubitril/Valsartan) Angiotensin receptor neprilysin inhibitor: Treatment of Heart failure with reduced ejection fraction to reduce the incidence of cardiovascular death.
Guideline oriented approach to lipid lowering in Canada. Study focused on patients with high LDL levels.
A Phase 3 Randomized, Placebo-Controlled, Double-Blind study to evaluate Upadacitinib in combination with Topical Corticosteroids in Adolescent and Adult subjects with moderate to severe Atopic Dermatitis.
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to evaluate Risankizumab in Adult and Adolescent subjects with moderate to severe Atopic Dermatitis.
Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 years) including a single open-label Arm(6-11years) study to evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric study participants with moderate to severe Chronic Plaque Psoriasis (PSO)
A Phase 2, Multicenter, Open-Label Extension study to evaluate the Long-Term Safety, Tolerability and Efficacy of ASN002 in subjects with moderate to severe Atopic Dermatitis.
North American Acute Coronary Syndrome (ACS) Reflective III Pilot. To give feedback to physicians on their post-ACS lipid-lowering management to support their decision-making and choice of therapies and thereby better achieve evidence-based,4,9 guideline-recommended10 management of post-ACS patients.
A Multi-Center, Randomized, Double Blind, Placebo- and Active Comparator-Controlled Please 3 study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in subjects with moderate-to-severe Plaque Psoriasis.
An Open-Label, Multi-Center extension study to characterize the long-team safety and efficacy of BMS-986165 in subjects with moderate-to-severe Plaque Psoriasis.
A Please 3 Randomized, Placebo-Controlled, Double-Blind study to evaluate Upadacitinib in Adolescent and Adult subjects with moderate to severe Atopic Dermatitis.
A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active controlled Study comparing the Safety and Efficacy of Upadacitinib to Dupilumab in adult subjects with moderate to severe Atopic Dermatitis.
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded study of Risankizumab compared to Secukinumab for the treatment of adult subjects with moderate to severe Plaque Psoriasis who are candidates for Systemic Therapy.
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety study of Ruxolitinib Cream followed by an extension period in participants with Vitiligo.
A Phase 2A, Randomized, Double-Blind, Placebo, Parallel Group, Multi-Center study to investigate the mechanism of action of Abrocitinib Monotherapy in Adult participants with moderate-to-severe Atopic Dermatitis.
Multicenter, Double-Blind, Randomized, Placebo-Controlled study to evaluate Safety, Tolerability, and Efficacy of lxekizumab in patients from 6 to Less than 18 years of age with moderate-to-severe Plaque Psoriasis.